Latest Medscape activity discusses emerging data for managing hemophilia and helps clinicians evaluate how to use them in clinical practice.
NHF is partnering with McMaster University, an international leader on clinical practice guidelines, to develop evidence-based guidelines for hemophilia care.
Bristol-Myers Squibb’s Daklinza™ (daclatasvir) combined with Gilead 's Sovaldi®,and AbbVie Inc.’s Technivie™ had high success rates in clearing hepatitis C virus.
New chapter covers assessment and management of typical bleeds, from joint bleeds to menorrhagia (heavy menstrual bleeding) and nosebleeds.
On July 8, 2015, the US Food and Drug Administration (FDA) set new rules to address drug shortages: a win for the bleeding disorders community.
Register now for these public workshops September 17 and 18 in Bethesda, MD. Hear the latest information on products and inhibitors.
Findings show that as people with hemophilia age, they will experience cardiovascular disease, which will need to be managed closely.
MASAC releases new documents on VWD, bypassing agents, HCV and treatment recommendations on current products.
The latest online educational activity discusses challenges in assessing and treating children with hemophilia from a nursing perspective.
“Managing Age-Related Clinical Issues in Hemophilia,” covers hypertension, cardiovascular disease, obesity, bone health and HCV.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car